While the method may sound unfamiliar, it has been clinically validated for decades and remains central to preventing ...
Research at Stanford Medicine suggests that a urine test may. be able to determine which patients will benefit from additional therapy.
Objectives: This study, conducted by the Bladder Cancer in Latin America (BLATAM) group, aims to analyze epidemiological and therapeutic data on non-muscle invasive bladder cancer (NMIBC) in Latin ...
Tokyo BCG is not inferior to TICE, and may help ease the BCG shortage. For treatment of high-grade (HG) non-muscle invasive bladder cancer (NMIBC), the Bacillus Calmette-Guérin (BCG) strain Tokyo-172 ...
With the rapid development of 16S rRNA sequencing and metagenomic technologies, the traditional concept of sterile urine has been completely overturned, and a diverse urinary microbiome has been ...
A phase 1/2, first-in-human study of AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), as monotherapy and in combination therapy in patients with locally advanced or metastatic ...
BROOKVILLE, Pa. (EYT) — Patients in northwestern Pennsylvania diagnosed with certain forms of bladder cancer now have access to a new treatment option at Penn Highlands Brookville. Bladder cancer is ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
In a phase 2 trial, intravesical TARA-002 showed a 72% complete response rate at any time among patients with high-grade NMIBC naïve to BCG. The investigational intravesical cell therapy TARA-002 ...
BCG has long been the standard of care for patients with high-risk non–muscle invasive bladder cancer (NMIBC) based on pivotal data from more than 25 years ago demonstrating that induction followed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results